Appili Therapeutics Inc Class A (APLIF) Price & Analysis

Q: What is Appili Therapeutics Inc Class A’s market cap?

Appili Therapeutics Inc Class A’s market cap is $2.20M.

Q: When is Appili Therapeutics Inc Class A’s upcoming earnings report date?

Appili Therapeutics Inc Class A’s upcoming earnings report date is Feb 17, 2026 which is in 60 days.

Q: How were Appili Therapeutics Inc Class A’s earnings last quarter?

Appili Therapeutics Inc Class A released its earnings results on Nov 13, 2025. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.

Q: Is Appili Therapeutics Inc Class A overvalued?

According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Appili Therapeutics Inc Class A pay dividends?

Appili Therapeutics Inc Class A does not currently pay dividends.

Q: What is Appili Therapeutics Inc Class A’s EPS estimate?

Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Appili Therapeutics Inc Class A have?

Appili Therapeutics Inc Class A has 121,266,120 shares outstanding.

Q: What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?

Appili Therapeutics Inc Class A reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Q: Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?

Currently, no hedge funds are holding shares in APLIF

Compare

82 Followers

APLIF Stock Chart & Stats

$0.02

>-$0.01(-8.10%)

At close: Jan 03 4:00 PM EST

$0.02

>-$0.01(-8.10%)

Day’s Range― - ―

52-Week Range<$0.01 - $0.03

Previous CloseN/A

Volume100.00

Average Volume (3M)43.77K

Market Cap

$2.20M

Enterprise Value$13.05M

Total Cash (Recent Filing)$348.68K

Total Debt (Recent Filing)$12.22M

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Feb 17, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding121,266,120

10 Day Avg. Volume6,020

30 Day Avg. Volume43,769

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)-0.39

Price to Sales (P/S)5.13

P/FCF Ratio-1.70

Enterprise Value/Market Cap5.93

Enterprise Value/Revenue65.33

Enterprise Value/Gross Profit69.12

Enterprise Value/Ebitda-14.81

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Appili Therapeutics Inc Class A News

Appili Therapeutics Raises C$177,500 in First Tranche of Private Placement

An update from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics has closed...

20h ago

Appili Therapeutics Reports Strong Q2 Results and Secures Major Funding for Infectious Disease Programs

An update from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics has announced...

1M ago

Appili Therapeutics Launches C$750,000 Private Placement to Boost Drug Development

An announcement from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics announced a...

1M ago

Appili Therapeutics prices 30M units at $0.025 in private placement

Appili Therapeutics (APLIF) announced a non-brokered private placement of up to approximately 30,000,000 units of the Company at...

1M ago

Appili Therapeutics to Showcase Biodefense Innovations at BARDA Symposium

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced its participation in...

2M ago

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has shared an announcement. Appili Therapeutics, in partnership with Vitalex...

3M ago

Appili Therapeutics, Vitalix awarded up to $40M contract from NIAID

Appili Therapeutics (APLIF) and its partner Vitalex Biosciences announced that the National Institute of Allergy and Infectious Diseases,...

3M ago

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives

An announcement from Appili Therapeutics Inc Class A ( ($TSE:APLI) ) is now available. Appili Therapeutics announced the...

3M ago

Appili Therapeutics to Showcase Tularemia Vaccine at NATO Conference

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has shared an announcement. Appili Therapeutics announced that Dr. Carl...

3M ago

Appili Therapeutics to present progress on Tularemia vaccine

Appili Therapeutics (APLIF) announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, will participate in the NATO Chemical,...

3M ago

Appili Therapeutics Strengthens Biodefense Partnerships and Advances Drug Development

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an announcement. Appili Therapeutics has reported its financial...

4M ago

Appili Therapeutics, colleagues publish manuscript on ATI-1701 efficacy

Appili Therapeutics (APLIF) announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine...

4M ago

Appili Therapeutics Demonstrates Efficacy of Tularemia Vaccine Candidate

Appili Therapeutics Inc Class A ( ($TSE:APLI) ) has issued an update. Appili Therapeutics announced a peer-reviewed publication...

4M ago

Appili Therapeutics Advances Infectious Disease Solutions with LIKMEZ Re-launch and Vaccine Developments

The latest announcement is out from Appili Therapeutics Inc Class A ( ($TSE:APLI) ). Appili Therapeutics has re-launched...

6M ago

APLIF FAQ

What was Appili Therapeutics Inc Class A’s price range in the past 12 months?

Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.

What is Appili Therapeutics Inc Class A’s market cap?

Appili Therapeutics Inc Class A’s market cap is $2.20M.

When is Appili Therapeutics Inc Class A’s upcoming earnings report date?

Appili Therapeutics Inc Class A’s upcoming earnings report date is Feb 17, 2026 which is in 60 days.

How were Appili Therapeutics Inc Class A’s earnings last quarter?

Appili Therapeutics Inc Class A released its earnings results on Nov 13, 2025. The company reported -$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.006.

Is Appili Therapeutics Inc Class A overvalued?

According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Appili Therapeutics Inc Class A pay dividends?

Appili Therapeutics Inc Class A does not currently pay dividends.

What is Appili Therapeutics Inc Class A’s EPS estimate?

Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Appili Therapeutics Inc Class A have?

Appili Therapeutics Inc Class A has 121,266,120 shares outstanding.

What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?

Appili Therapeutics Inc Class A reported an EPS of -$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?

Currently, no hedge funds are holding shares in APLIF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Appili Therapeutics Inc Class A

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.